Long-term effect of maternal obesity on pancreatic beta cells of offspring: reduced beta cell adaptation to high glucose and high-fat diet challenges in adult female mouse offspring
- 856 Downloads
Obesity is a global problem with high risks of cardiovascular diseases, stroke and type 2 diabetes. It is well known that maternal obesity affects offspring by inducing malformation, functional abnormalities in many organs and cells, and by increased risk of obesity and type 2 diabetes. However, little is known about abnormalities induced by maternal obesity in pancreatic beta cells of offspring.
We used mouse mothers with the Agouti yellow modification on a C57BL/6 background as a maternal model of normoglycaemic obesity, and produced Agouti-negative offspring. Half of the offspring were fed a high-fat diet. Offspring glucose tolerance was tested at different ages, and animals were killed at 50 weeks of age for islet function analysis.
Maternal obesity impaired glucose tolerance in female offspring fed a high-fat diet, and significantly reduced insulin secretion at 50 weeks of age in female offspring that had been fed a normal diet and high-fat diet. Insulin secretion and glucose potentiation from these islets were significantly reduced. Islet protein, DNA and insulin contents were increased while glyceraldehyde-3-phosphate dehydrogenase and transketolase activities were reduced in female offspring.
Our results indicate that maternal obesity has a long-term effect on the beta cells of female, but not of male, offspring, and leads to increased risk of gestational diabetes and type 2 diabetes in the offspring’s later lives.
KeywordsBeta cell adaptation Insulin secretion Islets of Langerhans Maternal obesity Offspring Type 2 diabetes mellitus
C57BL/6 J mice
More than 18% of American women meet the criteria for obesity [1, 2] and 18 to 38% of pregnant women in the United States are obese . Obesity during pregnancy has implications for morbidity and mortality in both mother and baby [4, 5]. One of the possible risks to the baby is the eventual development of type 2 diabetes . Maternal obesity could therefore be one of the factors contributing to the alarming rise in the prevalence of diabetes.
It is well known that a prenatal diabetic environment greatly increases the risk of type 2 diabetes in the offspring [7, 8, 9, 10]. The mechanism of this propensity to diabetes in the offspring is not well understood. Diabetes and obesity are frequently co-morbid conditions and maternal obesity could be one factor contributing to the ultimate development of diabetes in the offspring. Unfortunately, few studies have attempted to establish whether obesity in the absence of diabetes can promote glucose intolerance or diabetes in the offspring.
In the current study, we tested whether maternal obesity in mice, in the absence of diabetes, can impair glucose tolerance in genetically normal offspring. We used mothers carrying the Agouti (A y ) mutation on a C57BL/6 background. On this background, the A y mutation produces marked obesity without diabetes. Adult, genetically normal, offspring of A y -positive mothers were tested for their capacity to maintain normal glucose homeostasis.
Studies of the effect of maternal diabetes or obesity have demonstrated insulin resistance in the offspring [6, 11, 12]. However, diabetes will not occur unless there is also a reduction in pancreatic beta cell function [13, 14]. Until now, the impact of maternal diabetes or obesity on long-term beta cell function in the offspring has not been tested. In this study, we found sex-related changes in beta cell function due to maternal obesity. Our results indicate that maternal obesity can lead to problems in glucose tolerance in adult offspring and that deficits in the pancreatic beta cell play an important role.
Materials and methods
Body weight and fed blood glucose levels of Agouti and control mothers during pregnancy and 1 week after delivery
Fed blood glucose
A y L
Glucose tolerance test and insulin assay
After an overnight fast, mice were administered glucose intraperitoneally (1 g/kg body weight or 2 g/kg body weight as indicated). Blood samples were taken after tail snipping at various time points (0, 15, 30, 60 and 120 min), and blood glucose was determined as described above. Serum insulin levels at 0, 15, and 30 min time points were determined with the Ultrasensitive Mouse Insulin-ELISA Test Kit (Mercodia Company, Sylveniusgaten, Uppsala, Sweden).
Islets were isolated from mice by an adaptation of the Gotoh method : pancreas duct infiltration with collagenase, Histopaque gradient separation and hand-picking. Before performing measurements, islets were cultured for 1 h at 37°C in humidified air and 5% CO2 in RPMI 1640 supplemented with 5.5 mmol/l glucose, and 10% newborn calf serum, 2 mmol/l glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin (all from Gibco, Grand Island, NY, USA).
Ten islets were cultured in each 5-ml vial with 1 ml KRB (Krebs–Ringer bicarbonate buffer supplemented with 10 mmol/l HEPES, pH 7.4 and 0.1% BSA, bubbled with 5% CO2, 95% O2) containing 2.8 or 16.7 mmol/l glucose in a 37°C shaking water-bath as previously described . After incubation for 60 min, vials were moved from the water-bath to ice to stop the reaction, followed by a brief centrifugation at 4°C, 0.5 ml KRB was moved into a glass tube and stored at −20°C pending assay for insulin as described above.
Islet DNA, protein and insulin contents
DNA was measured by the Labarca method  and protein by a commercial kit that used BSA as standard (Bio-Rad, Hercules, CA, USA). Islets were homogenised in acid–ethanol and stored at −20°C pending assay for insulin contents as described above.
GAPDH activity assay
The assay measured the appearance of NADH absorbance at 340 nm as described by Lambeir et al. . Reaction mixtures (1 ml) contained 0.01 mol/l triethanolamine/HCl, pH 7.6, 1 mmol/l dithiothreitol, 1 mmol/l EDTA, 0.1 mol/l KCl, 10 mmol/l potassium phosphate, 1 mmol/l NAD and 0.8 mmol/l glyceraldehyde-3-phosphate. Reactions were initiated by addition of 10 μl of islet extract. Reactions were carried out at 25°C. Absorbance at 340 nm was measured on a Hitachi 2500 spectrophotometer (Technical Lab Services, Toronto, ON, Canada) for 10 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity was confirmed by measuring the conversion of NADH to NAD+ at 340 nm in the backward reaction starting with glycerate-3-phosphate using glycerate-3-phosphate kinase plus ATP as described previously .
Phosphofructokinase activity assay
Islets were sonicated on ice in 0.15 ml of extraction buffer containing 15 mmol/l K2PO4, pH 7.0, 100 mmol/l KCl, 2 mmol/l EDTA, 2 mmol/l phenylmethylsulfonyl fluoride, 0.2 mg/ml leupeptin and 50 μg/ml aprotinin. After centrifugation at 12,000 g for 15 min at 4°C, phosphofructokinase (PFK) activity was measured by a previously described method . Supernatant was added to 1 ml buffer that contained 50 mmol/l Tris/HCl, pH 8.0, 1 mmol/l EDTA, 2.5 mmol/l dithiothreitol, 5 mmol/l ammonium sulfate, 2 mmol/l MgCl2, 1 mmol/l ATP, 1 mmol/l fructose-6-phosphate, 0.16 mmol/l NADH, 0.4 U/ml aldolase, and 2.4 U/ml triose phosphate isomerase plus 0.8 U/ml glycerophosphate dehydrogenase mixture (Boehringer Mannheim, Indianapolis, IN, USA) in a quartz cuvette. The NADH metabolised was assessed at 340 nm by spectrophotometry. PFK activity was calculated based on 1 μmol fructose-1,6-diphosphate=2 μmol NADH consumed.
Transketolase activity assay
Islets were washed with PBS 0.5 ml, three times, and homogenised in 100 μl of 10 mmol/l HEPES, pH 7.4, 250 mmol/l sucrose, 2.5 mmol/l EDTA, 2 mmol/l cysteine, and 0.02% BSA. The catalytic activity of transketolase was measured spectrophotometrically at 340 nm at 25°C by the rate of NAD+ reduction in a coupled system with glyceraldehyde phosphate dehydrogenase . The reaction mixture (final volume 0.6 ml) contained 50 mmol/l glycylglycine, 5 mmol/l sodium arsenate, 0.25 mmol/l NAD+, 3 U glyceraldehydephosphate dehydrogenase, 3 mmol/l dithiothreitol, 2.5 mmol/l CaCl2, 0.1 mmol/l ThDP and 7 mmol/l phosphopentoses (xylulose-5-phosphate+ribose-5-phosphate); pH 7.6. The reaction was initiated by islet extract addition.
Data presentation and statistical methods
All data are expressed as means±SD. Unless otherwise stated, the listed n values represent the number of experiments performed. Comparisons between two groups were performed by Student’s t-test. Comparisons between multiple groups were performed by one-way or two-way ANOVA. A value of p<0.05 was considered significant.
Offspring birthweight and body weight
Blood glucose and serum insulin levels following a glucose challenge
Insulin secretion from isolated islets of control and Ay-negative female offspring
Islet protein, DNA and insulin contents in control and Ay-negative islets
Transketolase, GAPDH and PFK activities in 50-week-old control and Ay-negative female offspring islets
Clinical studies have demonstrated that maternal diabetes increases the offspring’s risk of developing type 2 diabetes [11, 23, 24]. Basic research in animal models of diabetes has shown similar effects [7, 25, 26]. However, neither clinical nor animal studies have clearly pinpointed whether it is the effects of maternal obesity or the effects of maternal diabetes that predisposes to type 2 diabetes in the offspring. To look at the effects of obesity independently of diabetes, we used A y mothers on a C57BL/6 background. As shown in Table 1, these female mice were obese but never became diabetic, even during pregnancy. Our analysis of their genetically normal offspring showed that maternal obesity induced impaired glucose tolerance in offspring with several features: (1) female A y -negative offspring on a normal diet exhibited impaired insulin secretion when challenged with an injection of 2 mg glucose/g body weight (Fig. 2); (2) in female offspring subjected to prolonged high-fat feeding, the impairment in insulin secretion due to an obese mother was exacerbated and these offspring also exhibited an abnormal glucose tolerance curve.
To our knowledge, this is the first report to show that obesity alone during pregnancy impairs glucose tolerance in offspring. This may contribute to the development of gestational diabetes and type 2 diabetes in these offspring. Since there are many times more obese mothers than diabetic mothers [1, 2, 3, 27], maternal obesity may be an important factor contributing to the overall rise of type 2 diabetes in the population.
The reduced serum insulin values in female A y -negative offspring suggested a defect in pancreatic beta cells. To test this directly we isolated islets from 50-week-old female offspring. The ability of glucose to stimulate insulin secretion was markedly reduced in A y -negative islets that had received a chronic HFD. This corresponded well to the low serum insulin levels we measured in vivo. High-fat feeding revealed functional deficits in A y -negative islets that were small or undetectable when A y -negative offspring were fed normal chow. At this time, it is unclear whether the impact of high-fat feeding was due to the need for beta cells to compensate for prolonged insulin resistance induced by high fat or to a direct toxic effect of elevated serum lipids on the beta cell [28, 29].
Despite relatively normal insulin secretion, islets from A y -negative female offspring that had been fed normal chow were not normal. They were significantly larger than control islets as indicated by increased protein, DNA and insulin content. In addition, we found that A y -negative female islets had markedly reduced transketolase and GAPDH activities. Transketolase is important for the pentose phosphate shunt that is needed for nucleic acid precursors  and may reduce high glucose stress . Low transketolase may render A y -negative islets vulnerable to additional damage. Low GAPDH may limit glycolytic flux and this could contribute to the impairment of glucose stimulated insulin secretion. We obtained low islet yields from high-fat fed mice; as a result we could not perform all assays on these islets. However, we were able to determine that high-fat feeding did not increase insulin content in A y -negative islets as it did in control islets. In addition, high-fat feeding caused a more severe decline in islet PFK activity in A y -negative islets. Both the failure to increase insulin content and the greater loss of PFK activity may have contributed to the decline in islet function of high-fat fed A y -negative islets.
The mechanisms by which maternal obesity impairs islet function in offspring are unknown. The fact that the change can be seen a full 50 weeks after delivery indicates that maternal obesity induces a change in developmental programming of the islet with permanent consequences for beta-cell function. Obesity is associated with abnormalities of lipid metabolism . Maternal non-estirified fatty acids can cross the placenta, and placental lipoprotein lipase hydrolyses triglycerides to fatty acids that can cross the placenta [31, 32]. Thus, increased serum levels of maternal fatty acids and triglycerides may increase fatty acid transfer to the fetus. Triglyceride levels are elevated in newborn infants of obese, nondiabetic mothers, in comparison with control subjects . Fatty acids are known to have detrimental effects on the adult beta cell [29, 34] and they may effect beta cell development as well. Oxidative stress occurs in the embryo during diabetic pregnancy , and also in the placenta of obese women . It is possible that obese pregnancy leads to beta cell oxidative stress that disrupts normal programming. Whatever the mechanism of damage, it was evident that female offspring were significantly and reproducibly more sensitive than male offspring. Other type 2 diabetes models exhibit a sex bias; however, this is generally towards greater sensitivity of males [37, 38]. Maternal obesity must have a different mode of damage to beta cells.
In summary, we have shown that maternal obesity causes glucose intolerance and a significant reduction in glucose-stimulated insulin secretion in A y -negative female offspring. Islet protein, DNA and insulin content in female offspring were increased but transketolase, GAPDH and PFK activities were reduced. These changes in A y -negative female offspring may contribute to the development of gestational diabetes and type 2 diabetes in later life. These results imply that the detrimental impact of maternal obesity on the beta cell may be another factor contributing to the epidemic of type 2 diabetes.
This work was supported by grants to Y. Q. Liu from the National Institutes of Health (P20 RR/DE17702 from the COBRE Program of the National Center for Research Resources) and the American Diabetes Association (Junior Faculty Award) and by grant DK58100 (P.N.E.). The authors wish to acknowledge the expert technical help of Barry Billings.
- 7.Aerts L, Holemans K, Van Assche FA (1990) Maternal diabetes during pregnancy: consequences for the offspring. Diabetes Metab Rev 6:147–167Google Scholar